Driving a consensus approach to improve the lives and fertility health of women stricken with endometriosis

May 27, 2024 09:00 AM +04 | By Cision

MANILA, Philippines , May 27, 2024 /PRNewswire/ -- Specialists in reproductive health in the Asia Pacific region are advancing a pathfinding initiative to improve the lives of millions of women around the world who suffer from endometriosis.

The debilitating condition affects up to 10 per cent of females with effects including chronic pain and potential fertility problems. Endometriosis robs many girls of their healthy teenage years often taking years before it is diagnosed.

While having a significant impact on the lives of girls and women with the disease, it also affects their families and workplaces. There is currently no cure for endometriosis, but there are treatment options to help manage its chronic impacts.

The Asia Pacific Initiative on Reproduction (ASPIRE) – a taskforce of scientists, clinicians, nurses and counsellors specialising in fertility health – is working to create centres and networks of expertise to treat endometriosis and an associated chronic condition called adenomyosis.

It is also bringing leaders in reproductive health together to advance strategies for fertility preservation for patients suffering from these conditions.

These twin objectives have been championed at the ASPIRE 2024 Congress in Manila, which gathered 1200 specialists to explore latest developments in the treatment of infertility that affects one in every six couples around the world.

Professor Neil Johnson, a Board Member of ASPIRE and Past President of the World Endometriosis Society, said the focus was on sharing knowledge and developing a consensus position on the treatment of endometriosis and adenomyosis among reproductive health specialists in APAC countries.

"We recognise the diversity of countries, economies, cultures and societies in the region, and aim to standardise best practice approaches in treating patients with these conditions while addressing potential threats to their fertility," he said.

"It requires a multi-disciplinary approach with shared decision making to assure the quality care of patients with endometriosis and adenomyosis in the Asia Pacific region and beyond.

"Currently, there is no consensus position in the world on fertility preservation for girls and women with these conditions.

"ASPIRE is building on its connections with major international bodies including the European Society of Human Reproduction and Embryology and the American Society for Reproductive Medicine to empower the region and help shape the future of reproductive health care throughout the world.

"In doing so, we are encouraging those in dialogue with governments and policy drivers to deliver appropriate funding and services for those whose health and fertility is threatened by endometriosis and adenomyosis."

The ASPIRE Congress in Manila is also advancing a reform blueprint called Fertility Counts to promote family friendly policies in the face of an alarming decline in fertility rates across the world, and particularly in many Asian Pacific countries.

For further information on the ASPIRE 2024 Congress, go to www.aspire2024.com 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalized advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.